4.6 Review

Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias

期刊

CANCERS
卷 13, 期 19, 页码 -

出版社

MDPI
DOI: 10.3390/cancers13194887

关键词

acute myeloid leukemia; clonal heterogeneity; evolutionary dynamics; drug resistance; prognosis

类别

资金

  1. Fondation ARC [PGA1-RC20180206836]
  2. Comite Ile-de-France Ligue Nationale Contre le Cancer [RS21-7591]
  3. Agence Nationale pour la Recherche, ANR STEM [ANR-19-CE27-0027-01]
  4. Canceropole Ile-de-France CLONE [2021-1-EMERG-54-CNRS]
  5. Fondation ARC (Aide Jeune Chercheur 2019)
  6. Agence Nationale de la Recherche (ANR) [ANR-19-CE27-0027] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

The text discusses the genetic and epigenetic alterations underlying acute myeloid leukemias and the intratumoral diversity of leukemic cells. It highlights the importance of understanding AML as an evolutionary process for developing novel therapeutic strategies. The impact of clonal diversity on patient outcomes and the mechanisms driving clonal dynamics are also emphasized.
Simple Summary Acute myeloid leukemias (AML) results from the accumulation of genetic and epigenetic alterations, often in the context of an aging hematopoietic environment. The development of high-throughput sequencing-and more recently, of single-cell technologies-has shed light on the intratumoral diversity of leukemic cells. Taking AML as a model disease, we review the multiple sources of heterogeneity of leukemic cells and discuss the definition of a leukemic clone. After introducing the two dimensions contributing to clonal diversity, namely, richness (number of leukemic clones) and evenness (distribution of clone sizes), we discuss the mechanisms at the origin of clonal emergence and the causes of clonal dynamics including neutral drift, and cell-intrinsic and -extrinsic influences on clonal fitness. After reviewing the prognostic role of leukemic diversity on patients' outcome, we discuss how a better understanding of AML as an evolutionary process could lead to the design of novel therapeutic strategies for this disease. Acute myeloid leukemias (AML) results from the accumulation of genetic and epigenetic alterations, often in the context of an aging hematopoietic environment. The development of high-throughput sequencing-and more recently, of single-cell technologies-has shed light on the intratumoral diversity of leukemic cells. Taking AML as a model disease, we review the multiple sources of genetic, epigenetic, and functional heterogeneity of leukemic cells and discuss the definition of a leukemic clone extending its definition beyond genetics. After introducing the two dimensions contributing to clonal diversity, namely, richness (number of leukemic clones) and evenness (distribution of clone sizes), we discuss the mechanisms at the origin of clonal emergence (mutation rate, number of generations, and effective size of the leukemic population) and the causes of clonal dynamics. We discuss the possible role of neutral drift, but also of cell-intrinsic and -extrinsic influences on clonal fitness. After reviewing available data on the prognostic role of genetic and epigenetic diversity of leukemic cells on patients' outcome, we discuss how a better understanding of AML as an evolutionary process could lead to the design of novel therapeutic strategies in this disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据